Valuing early-stage life sciences companies can be complex. Because product development can take several years and be capital intensive, obtaining an accurate valuation is essential to align management’s, the shareholders’, and current and potential investors’ understanding of estimated value.
With the adoption of AI-enabled ERP systems, companies can improve operational efficiency, compliance, reliability and decision-making speed.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
Technology that offers tools that conform, de-identify, link and aggregate data and data science tools like AI, machine learning and advanced analytics, can help those researching rare diseases overcome the hurdles they face in discovery and development.
By treating model governance as a proactive, integral part of operations rather than a box to check after the fact, life sciences organizations can uphold compliance, better allocate their resources, and gain a competitive edge.
The right AI model applied to the right problem exponentially enhances our ability to match patients with potentially life saving treatments faster and more effectively. The only “trick” required for truly successful AI integration — in life sciences or any other facet of the healthcare industry — is clarity of purpose.
MedCity News sat down with John Coleman, Business Unit Director at YSDS Life Science, to talk about the challenges of delivering temperature-sensitive goods and how to overcome them.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Recently, MedCity News spoke with a pair of top executives at global supercomputing ...
Strengthening Partnerships, Expanding Opportunity
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Leaders of WilmerHale’s life sciences practice share trends they see regarding acquisitions and initial public offerings.
Still recovering from a market correction two years ago, and with a scarcity of attractive targets and ongoing macroeconomic uncertainty, the life sciences dealmaking space is in a state of flux.
After a relatively slow 2016 for life sciences deals...
We live in a golden age of medicine. Never before have so many effective treatment options been available to so many people. And precision medicine is bringing new horizons, as well as the promise to further improve disease prevention, treatment, and ultimately find more cures. To keep moving toward personalized medicine approaches, more individuals would […]
This independent editorial series on healthcare and the law is sponsored by Lake Whillans, a distressed venture capital and litigation finance firm that helps companies facing litigation or arbitration. As states began to jump onto the pharmaceutical regulation bandwagon around the turn of the century, Porzio Bromberg & Newman brought John Ohoro on to help clients sift […]
Much like the calls for more data visualization in health IT at June’s Health Datapalooza, data visualizations can play a powerful role in improving the speed and quality of clinical trials. For example, the VP of ClinOps at a 20-year-old biotech start-up recently leveraged visualizations to help proactively manage a major last-minute patient enrollment challenge. […]